Allergan

Judge invalidates Allergan's key patents for dry-eye treatment Restasis

Allergan transfers drug patent to Mohawk tribe to sidestep lawsuits

Allergan to buy body-contouring product maker Zeltiq Aesthetics for $2.48 bn

Allergan to buy regenerative medicine specialist LifeCell for $2.9 bn

Cipla to sell entire 16.7% stake in US-based Chase Pharmaceuticals to Allergan Plc

Allergan to buy Tobira Therapeutics for $1.7 bn

Allergan to sell US distribution unit Anda to Teva for $500 mn

Merck & Co and Allergan eye US biotechnology company Biogen

Pfizer calls halt to $160bn merger with Allergan: report

New Treasury rules threaten Allergan-Pfizer merger

European regulator approves Teva's $40.5-bn Allergan drug unit deal with conditions

Allergen deal to help Pfizer save $35 bn in annual taxes: report

Pfizer to take over Allergan in historic $150-bn deal

Pfizer said to be in $150-bn merger talks with Allergan

Pfizer, Allergan mull largest pharma merger

Teva in talks to buy Allergan's generic-drug unit for $45 bn: report

Botox-maker Allergan Plc to buy Kythera Biopharmaceuticals for $2.1 bn

Actavis in talks to buy US Botox maker Allergan for around $60 billion: report

Botox maker Allergan in talks with new suitor

Valeant Pharmaceuticals plans to raise bid for Allergan

Valeant starts hostile takeover process for Allergan

Valeant raises offer for the second time this week for Allergan to $53.8 bn

Valeant raises Allergan bid to $49.44 bn: analysts say new offer still too low

Botox maker Allergan rejects Valeant's $45.7-b hostile bid

Allergan set to approach Shire Plc once again: report

Britain's Shire Plc recently rejected Allergan's takeover approach: report

Valeant tables hostile $45.7 bn bid for Botox maker Allergan

Valeant teams up with hedge fund to buy Botox maker Allergan for $42 bn

Allergan to buy SkinMedica's skin care unit for $350 million

Allergan explores sale of obesity intervention business

Allergan to buy more eye-care brands